Cargando…
Hemophagocytic lymphohistiocytosis in two patients following treatment with pembrolizumab: two case reports and a literature review
BACKGROUND: Hemophagocytic lymphohistiocytosis (HLH) is a rare and life-threatening state of immune hyperactivation. It has the highest mortality rate among all hematological immune-related adverse events (irAEs) of immune checkpoint inhibitors (ICIs) when treating various cancers. However, the pred...
Autores principales: | Wei, Yanqiu, He, Wei, Sun, Wei, Wu, Chaojie, Ren, Denghua, Wang, Xinmin, Zhang, Mingshun, Huang, Mao, Ji, Ningfei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459512/ https://www.ncbi.nlm.nih.gov/pubmed/36093533 http://dx.doi.org/10.21037/tcr-22-154 |
Ejemplares similares
-
Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis: an immunotherapeutic challenge
por: Kalmuk, James, et al.
Publicado: (2020) -
Hemophagocytic Lymphohistiocytosis in a Patient with Rheumatoid Arthritis on Pembrolizumab for Lung Adenocarcinoma
por: Akagi, Yu, et al.
Publicado: (2020) -
Two Infectious Agents Causing Hemophagocytic Lymphohistiocytosis
por: Atiq, Muhammad Umair, et al.
Publicado: (2021) -
COVID-19 and Pembrolizumab-Induced Secondary Hemophagocytic Lymphohistiocytosis: a Case Report
por: Ramos-Ruperto, Luis, et al.
Publicado: (2021) -
Hemophagocytic Lymphohistiocytosis
por: Kaçar, Ayşe Gonca, et al.
Publicado: (2022)